ANZCTR search results

In people with medial knee osteoarthritis, a 12-week program of strengthening the hip abductor and adductor muscles will reduce knee loading during walking gait, as measured by a reduction in the knee adduction moment.

This trial involves premenopausal women who after surgery for their breast cancer are found to have tumours which are hormone receptor positive (stimulated by hormones) and who also have positive axillary lymph nodes (‘glands under the arm pit’ containing cancer). For these women it is not known whether hormonal treatment alone is sufficient, or whether the addition of chemotherapy may be beneficial in reducing the incidence of disease recurrence and improving survival. Women who take part in this trial will all have their ovarian function suppressed and receive Tamoxifen. In addition, patients may or may not receive chemotherapy.

Trials of adjuvant tamoxifen in women with early breast cancer have demonstrated a highly significant improvement in 10-year survival. However it is not yet known how long women with early breast cancer should continue to take adjuvant tamoxifen. The ATLAS trial will determine if it is better to stop taking tamoxifen after 5 years, or continue taking it for another 5 years (10 years in total).

This clinical trial is for post and perimenopausal women who after having surgery for their breast cancer are found to have tumours which are stimulated by oestrogens (‘oestrogen receptor positive’) and who have cancer present in the glands of the arm pits (‘positive axillary lymph nodes’). For this group of women it is not known whether the addition of chemotherapy to hormonal treatment is beneficial in reducing disease recurrence and improving survival. Patients on this trial will all receive a hormonal therapy for their breast cancer. Some patients will also receive chemotherapy either at the same time, or before their hormonal treatment. This will be determined by a process called randomisation which is similar to the toss of a coin. This trial assesses the optimal way of combining these treatments for this type of breast cancer.

This study investigates if: (i) high-protein diets are superior to standard low-protein diet, and (ii) animal protein is superior to plant protein in weight management of overweight and obese individuals.

This project is investigating the optimal use of docetaxel and doxorubicin in the treatment of women with breast cancer and involved lymph nodes (N+). The efficacy of adjuvant chemotherapy in early breast cancer is well established by the international overview conducted by the Early Breast Cancer Trialist's Collaborative Group (EBCTCG). They have demonstrated the efficacy of adjuvant chemotherapy on reducing mortality and recurrence rates, but current regimens are far from optimal. Docetaxel (Taxotere), a new agent, has effectiveness and manageable side effects in the treatment of advanced breast cancer patients, and can plausibly improve outcomes for patients with early N+ breast cancer by optimal integration into current adjuvant chemotherapy regimens. This clinical trial is designed to compare whether it is advantageous to use docetaxel and/or doxorubicin in combination or sequentially with other currently available chemotherapy drugs

The ATAC trial is testing an alternative, new agent, to tamoxifen for women with early breast cancer. The new agent, Arimidex, is an aromatase inhibitor which acts to reduce the level of circulating oestrogen in post menopausal women. This drug seems to be well tolerated and also effective against breast cancer. The ATAC trial is a double blind study comparing 5 years of tamoxifen, with 5 years of Arimidex, and with 5 years of tamoxifen plus Arimidex. In addition, there are three very important sub studies which investigate the effects of the treatments on bone, the endometrium and quality of life (QOL). Australia had a high rate of recruitment to the QOL sub study and is also one of the few countries contributing to the endometrial sub study. The ATAC trial is one of the largest (over 9000 women internationally) and most rapidly completed breast cancer studies in the world. Active accrual to the main study and sub-studies was completed internationally in May 2000, and patient follow-up continues.

People with cancer of the oesophagus (gullet) often have trouble swallowing. Radiotherapy can help improve this problem. Using chemotherapy together with radiotherapy may work better but has more side effects. This trial will determine if it is better to use radiotherapy by itself or together with chemotherapy.

Breast milk is best for babies but is inadequate for very preterm infants without fortification with protein and some bone minerals. Currently, all breast milk for very preterm infants is fortified with a 'Human Milk Fortifier' but we're un-sure of the optimum level of protein that should be in the fortifier. This trial aims to determine if a higher level of protein added to fortifier will help preterm infants to grow better.

To investigate the effects of thigh muscles strengthening on knee joint loading and to examine if the effects are different in people with and without knee malalignment (bow legs)